Tranexamic + Mefenamic Tablets

Project Image
Thumb Image

Therapeutic Indication

Menorrhagia (heavy menstrual bleeding)
Dysmenorrhea (menstrual pain relief)
Postoperative pain and gynecological surgery
Dental pain, rheumatoid arthritis, osteoarthritis
+91 85919 78885

Tranexamic + Mefenamic

Tablet

Tranxemic acid is a synthetic derivative of the amino acid lysine. It is used to treat or prevent excessive blood loss during surgery and in various other medical conditions. It is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin, by binding to specific sites of both plasminogen and plasmin, a molecule responsible for the degradation of fibrin. Fibrin is a protein that forms the framework of blood clots. It has roughly eight times the antifibrinolytic activity of an older analogue, ε - aminocaproic acid.
Mefenamic acid is a non-steroidal anti-inflammatory drug used to treat pain, including menstrual pain. It is typically prescribed for oral administration.
Mefenamic acid decreases inflammation (swelling) and uterine contractions by a still unknown mechanism. However it is thought to be related to the inhibition of prostaglandin synthesis.

Speciality Gynecology | Pain Management
Tags Antifibrinolytic | NSAID | Gynecology
Strength
  • Tranexamic 500 mg
  • Mefenamic 250 mg
Packing Size
  • 10 Tablets

Check all Tablet Range

Click to know More

Mechanism

Tranexamic acid (AMCA) is a potent antifibrinolytic drug occurring in two isomeric forms; the antifibrinolytic potency resides in the transisomeric form. The main action of AMCA is blocking of the lysine-binding sites of the plasminogen molecule, which are of importance for the binding to fibrin. This prevents activation of plasminogen by plasminogen activator also absorbed to fibrin. AMCA can be administered perorally or intravenously and is excreted into the urine. It enters tissues and fluids in various concentrations and crosses the placenta. There is no evidence of a thrombogenic effect of AMCA, but in accordance with its action, it prolongs dissolution of fibrin deposits already formed. AMCA is a drug of high clinical value for the treatment of bleedings due to both systemic and local fibrinolysis Ponstel (mefenamic acid) is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models.

Pharmacokinetics

  • Tranexamic Acid: Bioavailability ~34%, half-life ~3.1 hours, excreted via urine
  • Mefenamic Acid: Bioavailability ~90%, half-life ~2 hours, metabolized hepatically (CYP2C9)

Side Effects

  • Gastrointestinal irritation (nausea, abdominal pain, diarrhea)
  • Dizziness, headache
  • Rare: thrombotic events (Tranexamic Acid)
  • Risk of renal/hepatic impairment with prolonged use

Contraindication

  • Pregnancy & lactation
  • Children
  • Active GI ulceration or chronic inflammation
  • Pre-existing renal disease
  • Hypersensitivity to NSAIDs or Tranexamic Acid

Interaction

  • Mefenamic Acid: Enhances activity of oral anticoagulants; ↑ GI irritation risk with alcohol
  • Tranexamic Acid: ↑ risk of thrombus formation with estrogens

Warning and Precautions

  • Monitor renal and hepatic function during prolonged therapy
  • Use with caution in patients with thromboembolic risk
  • Discontinue if GI bleeding or ulceration occurs
  • Not recommended in pediatric patients

Dosage

As directed by the Physician.

Disclaimer

All product details on this website are for reference and informational purposes only and are not directed at patients or consumers.
As a contract manufacturer, DM Pharma Pvt Ltd is not responsible for the marketing or end use of these products and disclaims all liability arising from reliance on this information.
Please consult a healthcare professional before using any medicinal product.